December 2019 Corporate Update
Harold H. Shlevin, Ph.D., president and chief executive officer of Galectin Therapeutics, provided an update on plans for the NASH-RX clinical trial of belapectin in patients with NASH cirrhosis without esophageal varices.
Galectin Therapeutics presentation at 2019 Anti-Fibrotic Drug Development (AFDD) Summit
Eliezer Zomer, Ph.D., Vice President, Discovery Research and Product Development for Galectin Therapeutics, presented at the 3rd Annual Anti-Fibrotic Drug Development (AFDD) Summit, held from Nov 18 – 20, 2019 in Boston, Massachusetts.
Corporate Update
An updated overview of the company’s activities and Clinical Phase studies with the galectin‑3 inhibitor GR‑MD‑02.
The Liver Line
The Liver Line is a community and online publication on liver health and liver disease. Liver Line is a central gathering place for patients, medical professionals and researchers to learn about the latest research in liver health and the treatment of diseases such as non-alcoholic steatohepatitis (NASH), liver fibrosis, and cirrhosis.